38% leiomyosarcoma
1.5% synovial sarcoma
17% liposarcoma (8% dedifferentiated, 4% myxoid, 3% well-differentiated, 1.5% pleomorphic, 1% liposarcoma not otherwise specified (NOS)
11% undifferentiated pleomorphic sarcoma
5% angiosarcoma
5% undifferentiated sarcoma NOS
3% extraskeletal myxoid chondrosarcoma
2% malignant peripheral nerve sheath tumor
2% myxofibrosarcoma
2% malignant solitary fibrous tumor
2% endometrial stromal sarcoma
1.5% chondrosarcoma
1.5% epithelioid sarcoma
1.5% fibrosarcoma
1.5% low-grade fibromyxoid sarcoma
5% other histologies, with one patient each

Source: FDA labeling

Lilly's Lartruvo Scores Broad FDA Approval In Orphan Sarcomas

More from Approvals